Apr 9, 2026 06:34AM H.C. Wainwright Downgrades Assertio Therapeutics (ASRT) to Neutral

Mar 18, 2026 07:54AM H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)

Mar 16, 2026 05:19PM Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c

Mar 16, 2026 05:19PM Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c

Jan 9, 2026 02:00PM Assertio publishes Rolvedon same-day dosing study in The Oncologist

Jan 5, 2026 06:41AM Assertio Therapeutics (ASRT) PT Raised to $35 at H.C. Wainwright

Nov 10, 2025 04:18PM Assertio Therapeutics (ASRT) Tops Q3 EPS by 27c, provides guidance

Oct 28, 2025 09:15AM Assertio names Mark Reisenauer as new CEO

Aug 12, 2025 06:42AM Assertio Therapeutics (ASRT) PT Lowered to $3 at H.C. Wainwright

Aug 11, 2025 04:07PM Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c

May 13, 2025 07:42AM Assertio Therapeutics (ASRT) Misses Q1 EPS by 9c

Mar 19, 2025 06:39AM Assertio Therapeutics (ASRT) PT Lowered to $3.50 at H.C. Wainwright

Mar 12, 2025 04:11PM Assertio Therapeutics (ASRT) Tops Q4 EPS by 1c ; Offers Guidance

Dec 17, 2024 08:32AM Assertio Holdings (ASRT) Appoints Mark Reisenauer to its Board

Dec 16, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)

Dec 13, 2024 08:00AM Assertio Holdings (ASRT) Announces Results of Rolvedon injection Same-Day Dosing Clinical Study

Nov 25, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)

Nov 11, 2024 04:02PM Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c

Nov 11, 2024 07:31AM Assertio Holdings (ASRT) Issues Response to Letter from Short-seller

Nov 8, 2024 09:00AM Buxton Helmsley Issues Letter to Assertio (ASRT) Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud

Aug 7, 2024 04:16PM Assertio Therapeutics (ASRT) Tops Q2 EPS by 4c ; Offers Guidance